SynthesisThe American journal of tropical medicine and hygiene2020
Biologics in Leprosy: A Systematic Review and Case Report.
Synthesis in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Unmet needs in the management of psoriasis in Latin America: a systematic review.Anais brasileiros de dermatologiaPooled it
- Methotrexate and Prednisolone compared to placebo and prednisolone in the treatment of severe Erythema Nodosum Leprosum: An international multicentre, double-blind randomised controlled clinical trial-MaPs in ENL.PLoS neglected tropical diseases · 2026Trial
- Dovramilast for Erythema Nodosum Leprosum in Patients With Leprosy in Nepal: Protocol for a Phase 2 Open-Label Pilot Study.JMIR research protocols · 2026Article
- "Reactions in Leprosy: Updated Insights Into Pathophysiology, Clinical Spectrum, and Therapeutic Approaches-A Narrative Review".Health science reports · 2026Article
- Infectious adverse events in patients treated with biotherapies in a tropical Amazonian context, French Guiana.BMC infectious diseases · 2026Article
- Bullous Type 2 Lepra Reaction: A Rare and Significant Case Report.Clinical case reports · 2025Article
- IFN-γ-Driven macrophage responses in the immunity toFrontiers in cellular and infection microbiology · 2025Review
- Leprosy in the 21st century: a comprehensive review of immunological mechanisms, diagnosis, and treatment.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Review
- Mapping Crohn's Disease Pathogenesis with Mycobacterium paratuberculosis: A Hijacking by a Stealth Pathogen.Digestive diseases and sciences · 2024Review
- A hypopigmented and enlarging granulomatous eruption.JAAD case reports · 2024Article
- Article
- Erythema nodosum after golimumab treatment in ankylosing spondylitis patients: a case report and literature review.Annals of medicine and surgery (2012) · 2023Article
- Methotrexate as a corticosteroid-sparing agent in leprosy reactions: A French multicenter retrospective study.PLoS neglected tropical diseases · 2023Article
- New insights at the interface between leprosy and immune-mediated rheumatic diseases.Frontiers in medicine · 2023Review
- Effective amelioration of the Lucio phenomenon with adjuvant tofacitinib therapy in a patient with dual infection ofAccess microbiology · 2023Article
- Case report: Cyclophosphamide pulse therapy for chronic recalcitrant erythema nodosum leprosum.Frontiers in medicine · 2023Article
- Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-α) for Patients With Erythema Nodosum Leprosum.Frontiers in medicine · 2022Article
- Treatment and Evaluation Advances in Leprosy Neuropathy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Susceptibility and resistance in leprosy: Studies in the mouse model.Immunological reviews · 2021Review
- Infections in the era of immunobiologicals.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor (TNF)-α inhibitors increase susceptibility to tuberculosis, but the effect of biologics on susceptibility to leprosy has not been described. Moreover, biologics may play a role in treating erythema nodosum leprosum (ENL). The objectives of this systematic review were to determine whether the development of clinical leprosy is increased in patients being treated with biologics and to assess the use of biologics in treating leprosy reactions. A systematic literature review was completed of patients with leprosy who received treatment with biologics either before or after a diagnosis of leprosy was confirmed. All studies and case reports were included for qualitative evaluation. The search yielded 10 cases (including one duplicate publication) of leprosy diagnosed after initiation of TNF-α inhibitors and four case reports of refractory ENL successfully treated with infliximab or etanercept. An unpublished case of persistent ENL responsive to infliximab is also presented. These data demonstrate that the use of TNF-α inhibitors may be a risk factor for developing leprosy or reactivating subclinical infections. Leprosy can present with skin lesions and arthritis, so leprosy should be considered in patients presenting with these signs before starting treatment with these agents. Leprosy should be considered in patients who develop worsening eruptions and neurologic symptoms during treatment with TNF-α inhibitors. Finally, TNF-α inhibitors appear effective in some cases of refractory ENL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.